July 4, 2017 / 5:53 AM / 2 months ago

BRIEF-Noxxon pharma first patients treated in phase I/II clinical trial of NOX-A12

July 4 (Reuters) - NOXXON PHARMA NV:

* FIRST PATIENTS TREATED IN PHASE I/II CLINICAL TRIAL OF NOX-A12 COMBINED WITH KEYTRUDA IN METASTATIC PANCREATIC AND COLORECTAL CANCER

* THE OPEN-LABEL TRIAL IS DESIGNED TO INCLUDE 20 PATIENTS, 10 PATIENTS FOR EACH METASTATIC PANCREAS AND COLORECTAL CANCER

* TOP-LINE DATA FOR ALL 20 PATIENTS FROM PART 1 IS TARGETED TO BE AVAILABLE IN Q2 2018, AND INITIAL RESPONSE-RATE DATA IN Q4 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below